News & Industry Updates

Press Releases Jan 03, 2024

ReAlta Life Sciences Strengthens Board of Directors with Appointment of Three Accomplished...

New appointments bring broad business management and commercial experience to support continued advancement of ReAlta’s multiple clinical programs Norfolk, VA...

Read More
Press Releases Oct 24, 2023

ReAlta Life Sciences Receives FDA Clearance for Phase 2 Trial of RLS-0071...

Third clinical indication under evaluation for RLS-0071, demonstrating the broad potential of ReAlta’s lead dual-action complement and innate inflammatory inhibitor...

Read More
Press Releases Oct 12, 2023

Senator Mark Warner Visits ReAlta Life Sciences’ Biotech Research Facility

Norfolk, VA, October 12, 2023 – ReAlta Life Sciences (“ReAlta”), Inc., a clinical mid-stage biotech company focused on harnessing the...

Read More
Press Releases Sep 06, 2023

ReAlta Life Sciences Receives FDA Clearance for Phase 2 Trial of RLS-0071...

ReAlta Life Sciences Receives FDA Clearance for Phase 2 Trial of RLS-0071 in Hospitalized Patients with Steroid-Refractory Acute Graft-Versus-Host Disease...

Read More
Press Releases Sep 05, 2023

ReAlta Poster Presentation at the European Respiratory Society 2023 International Congress

Norfolk, VA, September 5, 2023 – ReAlta Life Sciences (“ReAlta”), Inc., a clinical mid-stage biotech company addressing life-threatening rare diseases...

Read More
Press Releases Aug 01, 2023

ReAlta Doses First Patient in Phase 2 STAR Study of RLS-0071 for...

NORFOLK, Va., August 1, 2023 — ReAlta Life Sciences (“ReAlta”), Inc., a clinical mid-stage biotech company dedicated to addressing life-threatening...

Read More
Press Releases Jul 27, 2023

Congressman Bobby Scott Tours ReAlta Biotech Research Facility

Norfolk, VA, June 27, 2023 – ReAlta Life Sciences (“ReAlta”), Inc., a company addressing life-threatening rare diseases through harnessing the...

Read More
Press Releases Jun 01, 2023

ReAlta Life Sciences Announces Proof of Mechanism Data from the Phase 1b...

Norfolk, VA, June 1, 2023 – ReAlta Life Sciences (“ReAlta”), Inc., a company addressing life-threatening rare diseases through harnessing the...

Read More
Press Releases Mar 30, 2023

ReAlta Life Sciences Announces Poster Presentation at the American Thoracic Society 2023...

Presenting proof-of-mechanism clinical trial data in healthy volunteers of RLS-0071, the Company’s dual action complement inhibitor and innate anti-inflammatory product...

Read More